Whereas the signaling function of the interleukin 1 (IL-1) receptor type I (IL-1R I) has been well documented, the type II "receptor" has been suggested to act as a decoy target for this cytokine. Since IL-1 may represent a key target of the immunomodulatory and antiinflammatory properties of glucocorticoids (GC), the aim of this study was to investigate the effects of dexamethasone (Dex) on IL-1R expression in human polymorphonuclear leukocytes (PMN), which express predominantly the type II molecule (IL-1R II). We found that Dex augments the levels of steady state transcripts encoding the IL-1R I and, most prominently, those of IL-1R II. Dex induced both transcripts via transcription-dependent mechanisms and by prolongation of the mRNAs half-lives. Inhibition of protein synthesis superinduced basal and Dex-augmented IL-1R II mKNA, whereas it completely inhibited the induction by Dex of IL-1R I transcripts. Induction of IL-1R II mKNA by Dex was associated with augmented membrane expression and release of the type II IL-1 binding molecule. This effect was mediated by the GC receptor. Other steroids (17~5-estradiol, progesterone, and testostmone) were ineffective. The concentrations of IL-lot and IL-1 receptor antagonist required to displace the binding of IL-1/5 to the soluble form of the decoy molecule induced by Dex from PMN were, respectively, 100 and 2 times higher compared with IL-1/3. The induction by Dex of the type II receptor, a decoy molecule for IL-1, may contribute to the immunosuppressive and antiinflammatory activities of Dex.
G lucocorticoids (GC) are potent modulators of the immune and inflammatory responses in humans and experimental models. IL-1, a key mediator of inflammatory reactions (1), represents an important target of GC-mediated immunosuppressive activities. GC suppress IL-1 production by monocyte-macrophages, both in vitro and in vivo (2) (3) (4) (5) (6) (7) (8) (9) . In apparent contrast with the inhibitory activities of GC on IL-1, GC were found to increase the expression of 1L-1IL on different cell types, including human PBMC (10, 11) , PMN (11, 12) , and the B ceU llne Raji (13) .
Two IL-1Ks have been identified and cloned. The IL-1IL I is an 80-kD transmembrane protein expressed predominantly or exclusively in T lymphocytes, fibroblasts, and endothdial cells, whereas the most represented receptor on mydomonocytic ceils and B lymphocytes is the 68-kD (type II) IL-1R II (14, 15) . Although the IL-1R I has a demonstrated transmembrane signaling function (16) (17) (18) (19) (20) (21) (22) , the role of IL-1R II, which has a short (29-aa) cytoplasmic tail, is still a matter of investigation. Efforts aimed at defining a signaling function for IL-1R II using blocking mAbs have failed (22) . Moreover, studies on regulation of PMN survival by IL-1 and IL-4 have suggested that the IL-1R II acts as a decoy target for IL-1 (23) .
Given the importance of GC as antiinflammatory and immunosuppressive agents, this study was designed to conduct an in depth analysis of the regulation by GC of IL-1 receptors in human PMN.
Materials and Methods
Cells. Human PMN were separated from the peripheral blood of human healthy donors by Percoll gradient centrifugation (23) . Briefly, whole blood was fractionated by Ficoll gradient centrifugation (Seromed-Biochem KG, Berlin, Germany), and PMN, collected from the pellet, layered on top of 62% Percoll (Pharmacia, Uppsala, Sweden). PMN (~98% pure as assessed by morphology)
Reagents. Dexamethasone 11,1 Binding Assay. After treatment with 10 -7 M De~ for 12-14 h at 37~ 1-2 x 10 ~ PMN were incubated with decreasing concentrations of 12sI-IL-1/3 (180/zCi//Lg; NEN, Bad Homburg, Germany) in the presence or absence of a 200-fold molar excess of cold cytokine in 0.1 ml binding buffer (PBS-0.1% BSA-0.02% sodium azide; Sigma Chemical Co.) at room temperature for 1 h. To separate bound from free radiohbded ID1, cells were centrifuged over a cushion of silicon oil Scatchard analysis was performed by the LIGAND program (24) .
Northern Blot Analysis. KNA isohtion and analysis were as described (23) . Probes were a EcoKI-HindlII 477-bp fragment and a EcoKI-SalI 750-bp fragment from I b l g I and ID1R II cDNAs, respectively. Membranes were washed twice with 2x SSC/1% SDS (Merck & Co., Inc., Rahway, NJ) at 60~ and exposed for 24-36 h for IDIK I or 4-6 h for ID1K II expression at -80~ KNA transfer to membranes was checked by UV irradiation.
A~inity Cross-linking. Cross-linking experiments were described in detail (23) . Briefly, for surface affinity cross-linking, 30 x 106 PMN treated with 10 -7 M Dex for 14 h were incubated in binding buffer with 1 nM lzsI-IL-13. After addition of 1 mM disuccinimidyl suberate (DSS; Pierce Chemical Co., Rockford, IL), the cell pellet was lysed in 100/~1 lysis buffer (0.5% Triton X-100, 25 mM Hepes, I mM PMSF, 100/~g/ml aprotinin and leupeptin; Sigma Chemic.a1 Co.). The debris-free superuatant was analyzed by 8% SDS-PAGE under reducing conditions and dried gels were exposed to autoradiography for 1-3 d. For soluble covalent crosslinking, 30 x 106 PMN were cultivated with 10 -7 M Dex for 14 h in RPMI 1640 without serum at 37~ Medium was recovered and concentrated 10 times by membrane filtration (cut-off 10,000; Amicon, Beverly, MA). 200/zl were added with 1 nM l~sI-IL-1/5, with or without a 2-2000-molar excess of cold competitors (IL-lo~, ID13, and IL-lra), and incubated at 4~ for I h. After addition of 1 mM DSS at 4~ for 30 rain, samples were analyzed by gel electrophoresis as above. Densitometric analysis of autoradiographic signals has been performed with a scanning densitometer (GS 300; Hoefer Scientific Instruments, San Francisco, CA), calculating the area under the curve. (Fig. 2 , representative of four donors), indicating that gene transcription is involved in this phenomenon. We encountered considerable difficulties in performing run-off analysis in human circulating PMN. In one experiment with the lymphoblastoid B cell line Raji, Dex induced augmented levels of type II IL-1R transcription (data not shown). When transcript stability was examined, the halflives of type I and type II R transcripts in untreated cells
Results and Discussion
Dex Stimulates Predominantly IL-IR II mRNA Expression. Untreated PMN expressed abundant levels of the type II mRNA and these were considerably increased (4-10-fold, six donors) by Dex, with peak levels at 4-5 h (Fig. 1) . Visualized by Northern analysis, PMN have barely detectable or undetectable levels of type I IL-1R mKNA (11, 23) . Dex augmented also IL-1K I transcripts (three-to sixfold, six donors), but constitutive and inducible transcripts coding for IL-1R I were evident only after long times of exposure (the membranes shown in Hg. 1 were exposed to autoradiography for 25 h for the type I R and 5 h for type lI K transcripts). Thus, the predominant IL-1R transcripts induced by Dex in PMN are those coding for the IL-1R II. 
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IL-1 Decoy Receptor in Deaamethasone-treated Polymorphonuclear Cells were ~2 and 3 h, respectively (Fig. 3 , representative of three donors). Dex increased IL-1K transcript stability, prolonging the half-lives of type I and type II R to --15 and 7 h, respectively. Thus, Dex affects the expression of IL-1K I and IL-1K II at transcriptional and posttranscriptional levels. However, different mechanisms seem to underlie the Dex-mediated induction of these transcripts since inhibition of protein synthesis by cycloheximide (CH) superinduced the Dex-augmented expression of type II IL-1K mKNA but completely inhibited the induction of type I IL-1K transcripts (Fig. 2 , representative of four donors).
Dex.induced Surface Expression and Release of lL-1R II.
As expected (11, 12) , Dex caused a three-to sixfold increase in specific binding of IL-I~ to PMN, with unchanged Ka values (Table 1 ). Surface affinity cross-linking demonstrated an IL-1 receptor with a molecular mass consistent with the type II IL-1 binding protein (68 kD) (Fig. 4 A iUustrates a representative donor out of three tested).
Augmented surface expression of the type II IL-1K was associated with release of a soluble version of this IL-1 binding protein. Cross-linking revealed that the supernatants of Dextreated PMN contained an IL-l-binding protein of apparent The conditioned media were next concentrated and incubated with radiolabeled II.,1B and the different competitors at increasing molar excess (as indicated). After treatment with DSS, products were analyzed by SDS-PAGE under reducing conditions. The densitometric analysis of the antoradiographic film is illustrated below. molecular weight of "-'45 kD (Fig. 4 B) . This finding was confirmed in 10 different donors. Soluble IL-1 binding proteins of comparable size have been described in the supernatants from human mononudear cells and from the B cell line Raji (25) (26) (27) . Using mAbs, we recently established that the 45-kD IL-1 binding molecule released from PMN is a version of the type II IL-1tL (23) . Moreover, in preliminary experiments, Dex-induced release of the type II R as assessed using a specific ELISA assay (six donors, increase from 2.3-3.75-fold). A toxic effect of 10-6-10 -s M Dex can be ruled out, since neither LDH release nor cell viability (trypan blue dye exclusion) were affected by the treatment (data not shown). The release of a soluble form of the type II IL-1 binding protein by Dex was mediated by the glucocorticoid receptor, as two different competitive analogs (cortexolone and RU 486) prevented the Dex-mediated release of this IL-1 binding protein from PMN (Fig. 4 C) . RU 486 inhibited the induction of IL-1R II transcripts by Dex (not shown). Other steroids, including progesterone, 17-B-estradiol, and testosterone, were ineffective (Fig. 4 C) .
Relative A~nities of the Soluble T~qJe II Molecule to IL-lce, IL-1{3, and IL-1 Receptor Antagonist (IL-lra).
Since the membrane form of the decoy receptor binds IL-lce, IL-1B, and IL-lra with different affinities (28) (29) (30) , the binding properties of the corresponding soluble version were examined by competing the affinity cross-linking of radiolabeled IL-1/3 to the soluble IL-1R II with various concentrations of unlabeled IL-lo~, IL-113, and IL-lra. In a preliminary experiment, the competitive system used here was validated using recombinant soluble IL-1R I (data not shown). Ahhough formal binding analysis requires the purified sohble protein, the densitometric analysis of cross-linked products was used to demonstrate that the concentrations of IL-lra and IL-lc~ capable of inhibiting binding of radiolabded IL-113 by 50% were 2 and 100 times higher, respectively, compared with IL-113 (Fig. 5) .
Concluding Remarks. GC have a wide range of effects on various components of immune and inflammatory responses. The precise mechanisms underlying the immunosuppressive and anti-inflammatory activities of GC have not been completdy defined. GC have been shown to inhibit the synthesis of a series of cytokines involved in the regulation of inflammatory reactions, including IL-1 (2-9). The finding that GC, a major class of immunosuppressive and antiinflammatory agents, induce expression and rdease of the type II IL-1 binding molecule is consistent with the hypothesis that this molecule, perhaps inappropriately called a receptor, may indeed serve as a decoy target for IL-1 (23) .
